Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Learn more about whether Halozyme Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

yet traditionally undruggable targets with precision small-molecule therapeutics SAN DIEGO & BERLIN--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion) today announced that the first patient ...

At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting ...